Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus NEXPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus NEXPLANON.
ANNOVERA vs NEXPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Category C
Category C
Contraceptive
Contraceptive